FibroBiologics, Inc. (NASDAQ:FBLG)
| Market Cap | $6.34M-86.4% |
| Revenue (ttm) | $0 |
| Net Income | -$16.41M+11.3% |
| EPS | -$3.78+60.6% |
| Shares Out | 8.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,626 |
| Open | $0.87 |
| Previous Close | $0.83 |
| Day's Range | $0.70 - $0.87 |
| 52-Week Range | $0.62 - $9.60 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | $180.00(+25431.91%) |
| Earnings Date | Feb 23, 2027 |
About FBLG
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 23, 2027Earnings report
$FBLG stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in FBLG holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FBLG's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FBLG Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New FBLG patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FBLG from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in FBLG
| VXFVanguard Extended Market ETF | $58.90K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from FBLG’s recent data — informational, not investment advice
What’s Behind the Score
News check: Company reporting Q3 results with upcoming catalysts and advancing fibroblast therapy platform; IP portfolio update signals ongoing development progress.
